dc.date.accessioned | 2022-03-10T17:47:16Z | |
dc.date.available | 2022-03-10T17:47:16Z | |
dc.date.created | 2022-02-02T09:51:05Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Schuppan, Detlef Maki, Markku Lundin, Knut Erik Aslaksen Isola, Jorma Friesing-Sosnik, Tina Taavela, Juha Popp, Alina Koskenpato, Jari Langhorst, Jost Hovde, Øistein Lähdeaho, Marja-Leena Fucso, Stefano Schumann, Michael Török, Helga-Paula Kupcinskas, Jouzas Zopf, Yurdagul Lohse, Ansgar W. Scheinin, Mika Kull, Karin Biedermann, Luc Byrnes, Valerie Stellmach, Andreas Jahnsen, Jørgen Zeitz, Jonas Mohrbacher, Ralf Greinwald, Roland . A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease. New England Journal of Medicine. 2021, 385(1), 35-45 | |
dc.identifier.uri | http://hdl.handle.net/10852/92293 | |
dc.description.abstract | Background: In celiac disease, small intestinal transglutaminase 2 causes deamidation of glutamine residues in gluten peptides, which enhances stimulation of T cells and leads to mucosal injury. Inhibition of transglutaminase 2 is a potential treatment for celiac disease. Methods: In a proof-of-concept trial, we assessed the efficacy and safety of a 6-week treatment with ZED1227, a selective oral transglutaminase 2 inhibitor, at three dose levels as compared with placebo, in adults with well-controlled celiac disease who underwent a daily gluten challenge. The primary end point was the attenuation of gluten-induced mucosal damage, as measured by the ratio of villus height to crypt depth. Secondary end points included intraepithelial lymphocyte density, the Celiac Symptom Index score, and the Celiac Disease Questionnaire score (for assessment of health-related quality of life). Results: Of the 41 patients assigned to the 10-mg ZED1227 group, the 41 assigned to the 50-mg group, the 41 assigned to the 100-mg group, and the 40 assigned to the placebo group, 35, 39, 38, and 30 patients, respectively, had adequate duodenal-biopsy samples for the assessment of the primary end point. Treatment with ZED1227 at all three dose levels attenuated gluten-induced duodenal mucosal injury. The estimated difference from placebo in the change in the mean ratio of villus height to crypt depth from baseline to week 6 was 0.44 (95% confidence interval [CI], 0.15 to 0.73) in the 10-mg group (P = 0.001), 0.49 (95% CI, 0.20 to 0.77) in the 50-mg group (P<0.001), and 0.48 (95% CI, 0.20 to 0.77) in the 100-mg group (P<0.001). The estimated differences from placebo in the change in intraepithelial lymphocyte density were -2.7 cells per 100 epithelial cells (95% CI, -7.6 to 2.2) in the 10-mg group, -4.2 cells per 100 epithelial cells (95% CI, -8.9 to 0.6) in the 50-mg group, and -9.6 cells per 100 epithelial cells (95% CI, -14.4 to -4.8) in the 100-mg group. Use of the 100-mg dose may have improved symptom and quality-of-life scores. The most common adverse events, the incidences of which were similar across all groups, were headache, nausea, diarrhea, vomiting, and abdominal pain. Rash developed in 3 of 40 patients (8%) in the 100-mg group. Conclusions: In this preliminary trial, treatment with ZED1227 attenuated gluten-induced duodenal mucosal damage in patients with celiac disease. (Funded by Dr. Falk Pharma; CEC-3 EudraCT number, 2017-002241-30.). Copyright © 2021 Massachusetts Medical Society. | |
dc.language | EN | |
dc.title | A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease | |
dc.type | Journal article | |
dc.creator.author | Schuppan, Detlef | |
dc.creator.author | Maki, Markku | |
dc.creator.author | Lundin, Knut Erik Aslaksen | |
dc.creator.author | Isola, Jorma | |
dc.creator.author | Friesing-Sosnik, Tina | |
dc.creator.author | Taavela, Juha | |
dc.creator.author | Popp, Alina | |
dc.creator.author | Koskenpato, Jari | |
dc.creator.author | Langhorst, Jost | |
dc.creator.author | Hovde, Øistein | |
dc.creator.author | Lähdeaho, Marja-Leena | |
dc.creator.author | Fucso, Stefano | |
dc.creator.author | Schumann, Michael | |
dc.creator.author | Török, Helga-Paula | |
dc.creator.author | Kupcinskas, Jouzas | |
dc.creator.author | Zopf, Yurdagul | |
dc.creator.author | Lohse, Ansgar W. | |
dc.creator.author | Scheinin, Mika | |
dc.creator.author | Kull, Karin | |
dc.creator.author | Biedermann, Luc | |
dc.creator.author | Byrnes, Valerie | |
dc.creator.author | Stellmach, Andreas | |
dc.creator.author | Jahnsen, Jørgen | |
dc.creator.author | Zeitz, Jonas | |
dc.creator.author | Mohrbacher, Ralf | |
dc.creator.author | Greinwald, Roland | |
cristin.unitcode | 185,53,18,73 | |
cristin.unitname | K.G. Jebsen senter for cøliakiforskning | |
cristin.ispublished | true | |
cristin.fulltext | postprint | |
cristin.qualitycode | 2 | |
dc.identifier.cristin | 1996807 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=New England Journal of Medicine&rft.volume=385&rft.spage=35&rft.date=2021 | |
dc.identifier.jtitle | New England Journal of Medicine | |
dc.identifier.volume | 385 | |
dc.identifier.issue | 1 | |
dc.identifier.startpage | 35 | |
dc.identifier.endpage | 45 | |
dc.identifier.doi | https://doi.org/10.1056/NEJMoa2032441 | |
dc.identifier.urn | URN:NBN:no-94886 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 0028-4793 | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/92293/5/nejmoa2032441.pdf | |
dc.type.version | PublishedVersion | |